Suppr超能文献

锂盐、丙戊酸和卡马西平在双相情感障碍维持期的预防疗效:一项自然主义研究。

Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study.

作者信息

Peselow Eric D, Clevenger Steven, IsHak Waguih W

机构信息

aNew York Medical College, Richmond University Medical Center and Freedom From Fear, Staten Island, New York bWestern University for Health Sciences, Pomona cCedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

出版信息

Int Clin Psychopharmacol. 2016 Jul;31(4):218-23. doi: 10.1097/YIC.0000000000000097.

Abstract

Mood stabilizers are used clinically for the management of bipolar disorder. Prophylactic therapy with mood stabilizers is the primary treatment for preventing depressive and manic relapses in bipolar patients once they are stabilized. In this study, we examined the relative efficacy of the three most commonly used mood-stabilizing agents: lithium (Li), valproic acid (VPA), and carbamazepine (CBZ), in preventing relapse episodes. A total of 225 patients with bipolar disorder were included in the present analysis. Patients taking Li, VPA, or CBZ were followed up for up to 124 months, until suffering a manic, mixed, or depressive episode (relapse), or until the end of the study/study termination (no relapse), whichever came first. The median unadjusted survival time was 36 months for patients taking VPA, 42 months for patients taking CBZ, and 81 months for patients taking Li. These results indicate that patients stayed longer on Li, suggesting that it might have been better tolerated than either CBZ or VPA. χ-Analysis showed that patients taking Li were significantly less likely to experience relapse during the observational period than patients taking either VPA or CBZ (P<0.05). A Cox regression model showed that the hazard of experiencing relapse was significantly predicted by the total number of depressive (P=0.007) and manic symptoms (P=0.02) assessed before the observation period. In addition, after controlling for symptom covariates, the hazard of experiencing relapse was 1.66 times (95% confidence interval 1.03-2.67) or 66% higher for patients taking VPA compared with patients taking Li (P=0.037). Although the hazard of experiencing relapse was higher for patients taking CBZ compared with those taking Li, the risk was not elevated by a significant amount. Notwithstanding the limitations of the naturalistic design of this study, the differences in relapse prevention and survival time observed in these medications show Li fairing relatively better in prophylactic therapy.

摘要

心境稳定剂在临床上用于双相情感障碍的治疗。一旦双相情感障碍患者病情稳定,使用心境稳定剂进行预防性治疗是预防其抑郁和躁狂复发的主要治疗方法。在本研究中,我们考察了三种最常用的心境稳定剂:锂盐(Li)、丙戊酸(VPA)和卡马西平(CBZ)预防复发发作的相对疗效。本分析共纳入225例双相情感障碍患者。服用Li、VPA或CBZ的患者随访长达124个月,直至出现躁狂、混合或抑郁发作(复发),或直至研究结束/研究终止(未复发),以先发生者为准。服用VPA的患者未调整的中位生存时间为36个月,服用CBZ的患者为42个月,服用Li的患者为81个月。这些结果表明,服用Li的患者维持治疗的时间更长,提示Li可能比CBZ或VPA耐受性更好。χ分析显示,在观察期内,服用Li的患者比服用VPA或CBZ的患者复发的可能性显著更低(P<0.05)。Cox回归模型显示,观察期前评估的抑郁症状总数(P=0.007)和躁狂症状总数(P=0.02)可显著预测复发风险。此外,在控制症状协变量后,服用VPA的患者复发风险是服用Li的患者的1.66倍(95%置信区间1.03 - 2.67),即高出66%(P=0.037)。虽然服用CBZ的患者复发风险高于服用Li的患者,但风险升高幅度不显著。尽管本研究自然主义设计存在局限性,但这些药物在预防复发和生存时间方面的差异表明,Li在预防性治疗中表现相对更好。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验